CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET
Company Participants
Samarth Kulkarni – Chief Executive Officer
Conference Call Participants
Debjit Chattopadhyay – Guggenheim Partners
Debjit chattopadhyay
And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni. Thank you so much, Sam.
Samartha kulkarni
Thank you for having us.
Debjit chattopadhyay
Before we get into the Q&A, a very quick overview of where you are and sort of the key milestones for 2025.
Samartha kulkarni
Yeah. Happy to do that. I think we’ve been around as a company almost 10 years, which many people don’t appreciate and know about. But we’ve, ever since our founding, been focused on developing medicines that can transform the disease for patients with severe disease.
And we started with CAS — what is now CASGEVY, with sickle cell and thalassemia, and developed a transformative medicine that’s on the market now in a commercial setting. But beyond that, I’m also very proud of the pipeline that we’ve built and a very diverse pipeline.
For those who are new to the company, we have a focus in cardiovascular diseases with in vivo gene editing and where we take the CRISPR/Cas9 components, encapsulate it in a LNP particle, and we inject that into patients, and these LNP particles go to the liver and make an edit, reducing these cardiovascular risk factors. And I’ll talk more about that. So that’s one pillar that’s continuing to expand.
We have the best-in-class allogeneic CAR-T. And so what — with CAR-T, what we mean by that is taking cells or T-cells, from a healthy donor and engineering them and train them to kill a cancer. And we’ve also made additional
